Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

CytoDyn is a biotechnology company focused on the development of new therapies to combat infections with immune deficiency viruses. It has a unique and once-in-a-lifetime opportunity to possibly impact the IV/AIDS problem facing the world. CytoDyn will diligently pursue science and business opportunities, as presented, that may eventually benefit both shareholders and the world. CytoDyn developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The company intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. They conducting a Phase 1b/2 clinical trial to evaluate its targeted therapy for the treatment of metastatic triple-negative breast cancer, the most aggressive type of breast cancer.

Nanobiotix SA engages in research and development of nanoparticle-based technologies for the treatment of cancer. The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. It also engages in the development of magnetic particles and laser activated nanoparticles for the treatment and diagnosis of cancer. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

Baxter Healthcare SA engages in the development, production, and sale of healthcare systems and products. It also acquires and manages participations in pharmaceutical-chemical firms. The company was founded on December 7, 2000 and is headquartered in Glattpark, Switzerland.

Minerva Biotechnologies develops cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis. Its stem cell technology could transform the field of regenerative medicine. It discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. It is also the first company to generate human naïve state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate and are more easily directed to develop into functional mature cells, which could be used for transplant. It was founded in 1999 and is headquartered in Waltham, Massachusetts.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Entos develops next-generation genetic medicines using their proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

EpiAxis Therapeutics is pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells (CSC). Specifically, that target is the nuclear bound lysine-specific demethylase 1 (LSD1) & its upstream regulator, the theta isoform of protein kinase C (PKC theta). The research identifying this target and the intellectual property (IP) that resulted from this was developed by Professor Sudha Rao and colleagues at the University of Canberra (UC), Australia. The Company is focused initially on the prevention of metastatic breast cancer, with other CSC mediated diseases such as ovarian, pancreatic, colon, melanoma, lung and liver cancers to be pursued later. EpiAxis is positioning itself to become the leading cancer recurrence prevention company with its proprietary LSD1 & PKC theta inhibitors included in the standard of care (SoC) for cancer.

eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

General Oncology is developing a pipeline of treatments for solid metastatic cancers and cancers of the blood. They have a clinical trial underway for an investigational treatment for BRCA-related metastatic pancreatic cancer. General Oncology is sponsoring a clinical trial (Clinical Trial GO-1) for its investigational treatment for BRCA-related metastatic pancreatic cancer. The treatment involves two cycles of chemotherapy using melphalan, BCNU, vitamin B12b, and vitamin C, along with two stem cell transplants to reverse bone marrow suppression. The trial is currently open for enrollment.

ZIOPHARM Oncology is an American biopharmaceutical company headquartered in Boston, Massachusetts, that develops novel therapeutics for the treatment of cancer. ZIOPHARM has three oncology therapeutics in clinical development: IL-12 DNA, indibulin and darinaparsin. In 2011, ZIOPHARM established a partnership with Intrexon Corporation to develop and commercialize DNA therapeutics based on Intrexon's synthetic biology technology platform. The exclusive channel partnership between Intrexon and ZIOPHARM has been established specifically for the field of human oncologic therapeutics. Under the partnership, ZIOPHARM will be responsible for conducting preclinical and clinical development of candidates, as well as for other aspects of manufacturing and the commercialization of the candidates.

Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ.

Aravive Biologics, Inc. develops novel targeted therapeutics in oncology. The company was founded by Amato Giaccia and Albert Koong and is headquartered in Houston, TX.

Institut Jean Paoli & Irene Calmettes is a non-profit organization engaging in fighting cancer. The company is headquartered in Marseille, France.